| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.088 | 0.08 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.08 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.064 | 0.08 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.088 | 0.08 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.063 | 0.08 |